MoonLake Immunotherapeutics filed SEC Form 8-K: Regulation FD Disclosure

$MLTX
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $MLTX alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $MLTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MLTX

DatePrice TargetRatingAnalyst
1/17/2025$62.00 → $82.00Neutral → Buy
Goldman
11/5/2024$92.00 → $73.00Outperform
Wedbush
8/26/2024Outperform → Peer Perform
Wolfe Research
6/25/2024$104.00Outperform
Oppenheimer
4/2/2024$62.00Neutral
Goldman
2/15/2024$77.00Outperform
Wolfe Research
12/8/2023$72.00Buy
Citigroup
11/2/2023$74.00Buy
Stifel
More analyst ratings

$MLTX
Press Releases

Fastest customizable press release news feed in the world

See more
  • MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

    Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis (PsA) following positive FDA and EMA regulatory feedback, continuing to support a potential best-in-class profile across two key indicationsInitiated three new trials in the beginning of 2025 with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA)Signed a three-year technology partnership with Komodo Health to advance research on inflam

    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

    New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA)MoonLake now independently running seven trials in 2025 across large dermatology and rheumatology indications: adult HS, adolescent HS, psoriatic arthritis (PsA), PPP and axSpAPhase 2 and Phase 3 data read-outs across all target indications expected in 2025 (adult HS, and PPP) and 2026 (adolescent HS, PsA and axSpA)Data from the Phase 3 VELA-TEEN trial may be combined with the Phase 3 VELA program in adults with moderate-t

    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Clear Street Launches Healthcare & Biotechnology Equity Research

    Comprehensive Biotechnology sector market analysis and investment insights complement recently launched Disruptive Technology and Energy Transition franchises Clear Street, ("Clear Street", "the Company") a cloud-native financial technology firm on a mission to modernize the brokerage ecosystem, today announced the expansion of its recently launched equity research offering with the addition of Healthcare, initially focused on the biotechnology sector. The expanded research offering complements Clear Street's leading prime brokerage and clearing solutions for its rapidly growing client base of asset managers, institutions and professional traders across equities, fixed income, derivatives

    $CGEM
    $CRGX
    $DCTH
    $ELVN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

$MLTX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$MLTX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$MLTX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$MLTX
SEC Filings

See more

$MLTX
Financials

Live finance-specific insights

See more
  • MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

    Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis (PsA) following positive FDA and EMA regulatory feedback, continuing to support a potential best-in-class profile across two key indicationsInitiated three new trials in the beginning of 2025 with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA)Signed a three-year technology partnership with Komodo Health to advance research on inflam

    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

    MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026Strong market performance of other IL-17 inhibitors in hidradenitis suppurativa (HS) and other inflammatory indications validating large market opportunity for sonelokimabPhase 3 clinical program in HS is progressing as per plan with primary endpoint readout anticipated as of mid-2025Preparations for Phase 3 clinical program in psoriatic arthritis (PsA) completed with patient enrollmen

    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

    MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3 VELA program of the Nanobody® sonelokimab in hidradenitis suppurativa ("HS"), with topline results anticipated as of mid-2025Secured positive feedback from both U.S. Food and Drug Administration ("FDA") and the E.U. European Medicines Agency ("EMA") on the regulatory path for the Phase 3 program of the Nanobody® sonelokimab in psoriatic arthritis ("PsA") and outlined the clinical plan with topline results anticipated in end-2026Ended the quarter with $519.8 million in cash, cash equivalents and short-term marketable debt securities, expected to

    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

$MLTX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more